Loading...

Crop Research

Comparative studies on antifungal activity of plant extract and commercially available antibiotics against fungi causing mucormycosis

 

DOI: 10.31830/2454-1761.2025.CR-1040    | Article Id: CR-1040 | Page : 433-440
Citation :- Comparative studies on antifungal activity of plant extract and commercially available antibiotics against fungi causing mucormycosis. Crop Res. 60: 433-440
MEHAK JAIN, RAM KUMAR PUNDIR AND RAJESH YOGI ramkumar.e11204@cumail.in
Address : Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, Gharuan, Mohali - 140413, Punjab, India
Submitted Date : 7-07-2025
Accepted Date : 26-07-2025
Online Published:

Abstract

In the present Covid era, mucormycosis (black fungus) is mostly explored by the researchers. It is relatively rare, but also very serious as far as no proper treatment of this fungal infection that commonly causes infection in immune compromised or diabetic patients and COVID patients due to prolonged use of steroids. The present study was designed to screen the antifungal activity of Curcuma longa (Turmeric) a medicinal plant against Absidia blakesleeana and Rhizomucor pusillus by using Agar Well Diffusion method. The antibiotic susceptibility pattern of R. pusillus and A.  was determined by Kirby-Bauer disc diffusion method. This research work was conducted between 1st January 2024 and 28th February 2025. The antifungal activity of C.  longa was screened and examined the zone of inhibition of 12mm in petroleum ether extract in A. blakesleeana and none of the activity was observed in either of the solvents in R. pusillus. Ketoconazole (36mm) was found to be most effective against R. pusillus. The antibiotic susceptibility pattern of A. blakesleeana exhibited sensitive against Clotrimazole (22 mm). The phytochemical analysis of C. longa revealed the presence of alkaloids, saponins, tannins, glycosides and flavonoids compounds in the solvent petroleum ether.

Keywords

Absidia blakesleeana antibiotic susceptibility antifungal activity mucormycosis Rhizomucor pusillus

References

AL-Khikhani, F. H. O. (2020). Amphotericin B from antifungal to antiviral therapy: promising modern therapeutic branch. Res. Results Pharma. 6: 57-65. doi:10.3897/ rrpharmacology.6.53649.
Badali, H., Gibas, C. C., Carthy, D. M., Patterson, H., Sanders, C., David, P. M., Mele, J., Fan, H. and Wiederhold, N. P. (2021). Epidemiology and antifungal susceptibilities of mucoralean fungi in clinical samples from the United States. J. Clin. Microbiol. 59: doi:10.1128/JCM.01230-21.
Bauer, A. W., Perry, D. M. and Kirby, W. M. (1959). Single disc antibiotic sensitivity testing of Staphylococci. AMA Arch. Intern. Med. 104: 208-16. doi:10.1001/archinte.1959. 00270080034004.
Borman, M. A., Fraser, M., Patterson, Z., Palmer, D. M and Johnson, M. B. (2021). In vitro antifungal drug resistance profiles of clinically relevant members of the mucorales (Mucoromycota) especially with the newer triazoles. J. Fungi. 7:  doi:10.3390/jof7040271.
Cornely, O. A., Alastruey, I. A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K. and Lewis, R. E. (2019). Global guideline for the diagnosis and management of mucormycosis: An initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect. Dis. 19: 405-21.
Dismukes, W.E. (2000). Introduction to Antifungal Drugs. Clin. Infect. Dis. 30: 653-57.
Donovick, R., Gold, W., Pagano, J. F. and Stout, H. A. (1956). Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. Antibiot. Annu. 3: 579-86.
Faway, E., Staerck, C., Danzelle, C., Vroomen, S., Courten, C., Mignon, B. and Poumay, Y. (2021). Towards a standardized procedure for the production of infective spores to study the pathogenesis of dermatophytosis. J. Fungi. 7: 1-19. doi:10.3390/jof7121029.
Govindarajan, A., Bistas, G. K., Ingold, J. C., Patel, P. and Aboeed, A. (2023). Fluconazole. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
Hussain, K. M., Ahmed, S., Khan, A., Siddiqui, J. A., Khatoon, S. and Jahan, S. (2023). Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents. Eur. J. Med. Chem. 246: 1-17.
Janowaski, M., Demchuk, M. O. and Wujec, M. (2024). Fluconazole analogs derivatives: An overview of synthesis chemical transformation and biological activity. Molecules 29:  doi:10.3390/molecules29122855.
Li, Z. and Denning, W. D. (2023). The impact of corticosteroids on the outcome of fungal disease: A systematic review and meta-analysis. Res. Results Pharmacol. 17: 54-70.
Mohana, S., Manimegalai, V., Sundaramoorthy, K. A. (2023). Review on clotrimazole loaded trans ethosomal gel for candidiasis. World J. Pharm. Res. 13: 57-90.
Morrissey, C. O., Kim, Y. H., Garnham, K., Dao, A., Chakrabarti, P. J. R., Izquierdo, A. A., Harrison, T. S., Bongomin, F., Galas, M., Siswanto, S., Dagne, D. A., Roitberg, F., Gigante, V., Sati, H., Alffenaar, J. W. and Beardsley, J. (2024). Mucorales: A systematic review to inform the World Health Organization priority list of fungal pathogens. Medical Mycol. 62: 1-24.
Naseer, S., Khalid, S., Parveen, S., Abbass, K., Song, H. and Achim, V. M. (2023). COVID-19 outbreak: Impact on global economy. Front. Public Health 10: 1-13.
Niazkar, R. H., Zibaee, B., Nasimi, A. and Bahri, N. (2020). The neurological manifestations of COVID-19: A review article. Neurol. Sci. 41: 1667-71. doi:10.1007/s10072-020-04486-3.
Petrikkou, E., Tudela, R. L. J., Estrella, C. M.,  Gómez, A. and Mellado, E. (2001). Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. J. Clin. Microbiol. 39: 1345-47.
Pundir, R. K. and Jain P. (2021). Mucormycosis (The black fungus) associated with COVID-19 patients- epidemiology, pathogenesis, diagnosis and treatment regimes. Int. J. Pharm. Sci. Res. 12: 1-17.

Raj, P and Bhati, K. R. (2022). Tangential role of therapeutics in covid-19 induced mucormycosis: A review. Archives 1: doi:10.55927/eajmr.v1i4.106.
Santosh, D. T., Mandal, D. and Tiwari, K. N. (2021). Yield and quality response of turmeric (Curcuma longa) under drip irrigation and plastic mulch. Res. Crop. 22: 959-67.
Sarkar, P.  Yarlagadda, V. Ghosh, C. and Haldar, J. (2017). A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics Med. Chem. Comm. 8: 516-33.
Sasi, S. E., Akshaya, P. C., Sebastian, D. P. and George, S. (2021). Influence of stress signals on phenotypic characters, rhizome yield and secondary metabolite production of turmeric (Curcuma longa) cv. ‘Pragathi’. Crop Res. 56: 329-35.
Schober, S., Cabanillas, K. M., Stanchi, R. A., Pfeiffer, M., Tsiflikas, I., Wiegand, G., Martinez, L. Q., Haen, S., Ebinger, M., Lang, P., Handgretinger, R., Doring, M. (2021). Fulminant Rhizomucorpusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature. Med. Mycol. Case Rep. 32: 4-9.
Sharma, A., Yogi, R., Pandey, P. R., Jain, P., Jain, M. and Pundir, R. K. (2024). Antimycotic properties of some antidiabetic medicinal plants against Absidiablakesleeana (A causative agent of mucormycosis: The black fungus). J. Food Chem. Nanotechnol. 10: 144-50. doi:10.17756/jfcn.2024-s1-019.
Sousa, F., Nascimento, C., Ferreira, D., Reis, S. and Costa, P. (2023). Reviving the interest in the versatile drug nystatin: A multitude of strategies to increase its potential as an effective and safe antifungal agent. Adv. Drug Deliv. Rev. 199: 1-35.
Viecceli, C., Mattos, V. C. A., Hirakata, N. V., Garcia, P. S., Rodrigues and C. D. T. and Czepielewski, A. M. (2023). Ketoconazole a second- line treatment for Cushing’s disease after transsphenoidal surgery: systematic review and meta- analysis. Front. Endocrinol. 14: 1-8.
Yassin, Z., Amirzargar, B.,  Ghasemi, R.,  Valizadeh, F. and Fattahi, M. (2023). Comparison of acidifying agents and Clotrimazole for treatment of otomycosis: a comprehensive one- way mini- review. Curr. Med. Mycol. 9: 45-51. doi:10.18502/cmm.2023.345035.1402.

Global Footprints